Acorda patents expiration
1. Ampyra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5540938 | ACORDA | Formulations and their use in the treatment of neurological diseases |
Jul, 2018
(5 years ago) | |
| US9918973 | ACORDA | Sustained release aminopyridine composition |
Dec, 2024
(7 months from now) | |
| US8663685 | ACORDA | Sustained release aminopyridine composition |
Jan, 2025
(8 months from now) | |
| US8440703 | ACORDA | Methods of using sustained release aminopyridine compositions |
Apr, 2025
(11 months from now) | |
| US8354437 | ACORDA | Method of using sustained release aminopyridine compositions |
Dec, 2026
(2 years from now) | |
| US8007826 | ACORDA | Sustained release aminopyridine composition |
May, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jan 22, 2017 |
| New Chemical Entity Exclusivity(NCE) | Jan 22, 2015 |
Drugs and Companies using DALFAMPRIDINE ingredient
NCE-1 date: 22 January, 2014
Market Authorisation Date: 22 January, 2010
Treatment: Improvement of walking in patients with multiple sclerosis (ms)
Dosage: TABLET, EXTENDED RELEASE;ORAL
AMPYRA family patents
2. Inbrija patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8628754 | ACORDA | Highly efficient delivery of a large therapeutic mass aerosol |
Jun, 2020
(3 years ago) | |
| US6921528 | ACORDA | Highly efficient delivery of a large therapeutic mass aerosol |
Jun, 2020
(3 years ago) | |
| US6514482 | ACORDA | Pulmonary delivery in treating disorders of the central nervous system |
Sep, 2020
(3 years ago) | |
| US6613308 | ACORDA | Pulmonary delivery in treating disorders of the central nervous system |
Sep, 2020
(3 years ago) | |
| US6979437 | ACORDA | Pulmonary delivery in treating disorders of the central nervous system |
Sep, 2020
(3 years ago) | |
| US7146978 | ACORDA | Inhalation device and method |
Apr, 2021
(3 years ago) | |
| US6858199 | ACORDA | High efficient delivery of a large therapeutic mass aerosol |
Nov, 2021
(2 years ago) | |
| US7556798 | ACORDA | Highly efficient delivery of a large therapeutic mass aerosol |
Nov, 2021
(2 years ago) | |
| US7384649 | ACORDA | Particulate compositions for pulmonary delivery |
Nov, 2022
(1 year, 4 months ago) | |
| US9155699 | ACORDA | Pulmonary delivery for levodopa |
Mar, 2023
(1 year, 1 month ago) | |
| US8586093 | ACORDA | Pulmonary delivery for levodopa |
Mar, 2023
(1 year, 1 month ago) | |
| US8404276 | ACORDA | Pulmonary delivery for levodopa |
Mar, 2023
(1 year, 1 month ago) | |
| US7182961 | ACORDA | Particulate compositions for pulmonary delivery |
Feb, 2024
(a month ago) | |
| USRE43711 | ACORDA | Pulmonary delivery for levodopa |
Feb, 2029
(4 years from now) | |
| US8945612 | ACORDA | Capsules containing high doses of levodopa for pulmonary use |
Nov, 2032
(8 years from now) | |
| US8545878 | ACORDA | Capsules containing high doses of levodopa for pulmonary use |
Nov, 2032
(8 years from now) | |
| US9393210 | ACORDA | Capsules containing high doses of levodopa for pulmonary use |
Nov, 2032
(8 years from now) | |
| US8685442 | ACORDA | Capsules containing high doses of levodopa for pulmonary use |
Nov, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 21, 2021 |
Drugs and Companies using LEVODOPA ingredient
Market Authorisation Date: 21 December, 2018
Treatment: Intermittent treatment of off episodes in patients with parkinson's disease treated with carbidopa/levodopa by inhalation of levodopa powder particles through a single breath activated step; Intermitt...
Dosage: POWDER;INHALATION
INBRIJA family patents